Mom will teach you NMR

New Drug Approvals

Dedicated to all moms in the world
C=O group is dad
O atom is mom
Carbonyl is dad and oxygen mom hence c labelled methyl has higher chemical shift  and gets a little more attention
SEE BELOW
NMR IS EASY
A chemical has Formula: C5H10O2
C5H10O2
Rule 2, omit O, gives C5H10
5 – 10/2 + 1 = 1 degree of unsaturation.
Look for 1 pi bond or aliphatic ring.
IR
IR spectrum
The band at 1740 indicates a carbonyl, probably a saturated aliphatic ester. The bands at 3000-2850 indicate C-H alkane stretches. The bands in the region 1320-1000 could be due to C-O stretch, consistent with an ester.
NMR spectrum
Structure answerThis is the structure. See if you can assign the peaks on your…

View original post 107 more words

Advertisements

Cocrystals

New Drug Approvals

Abstract Image

Active pharmaceutical ingredients (APIs) are frequently delivered to the patient in the solid state as part of such dosage forms as tablets, capsules, etc.In this context the ability to deliver the drug to the patient in a safe, efficacious and cost-effective way depends largely on the physicochemical properties of the APIs in the solid state, and ……..read more

http://www.allfordrugs.com/cocrystals/

View original post

Efficient and selective copper-catalyzed organic solvent-free and biphasic oxidation of aromatic gem-disubstituted alkenes to carbonyl compounds by tert-butyl hydroperoxide at room temperature

ORGANIC CHEMISTRY SELECT

Efficient and selective copper-catalyzed organic solvent-free and biphasic oxidation of aromatic gem-disubstituted alkenes to carbonyl compounds by tert-butyl hydroperoxide at room temperature

Green Chem., 2014, 16,3013-3017
DOI: 10.1039/C3GC42624F, Communication
Md. Munkir Hossain, Wei-Kai Huang, Hung-Jie Chen, Pei-Han Wang, Shin-Guang Shyu
Biphasic Cu(II) catalyzed selective oxidative cleavage of aromatic gem-disubstituted alkenes to carbonyl compounds using tert-butyl hydroperoxide at room temperature.
Copper-catalyzed alkene oxidation to carbonyl compounds by tert-butyl hydroperoxide (TBHP) under organic solvent-free and biphasic conditions at room temperature is selective for the aromatic gem-disubstituted alkenes. Enhanced reactivity was observed in the presence of 2,9-dimethyl-1,10-phenanthroline (neocuproine). The reaction is economically attractive because the yield is high, and separation of products and recycling of the catalyst are easy.

ANTHONY MELVIN CRASTO

THANKS AND REGARD’S
DR ANTHONY MELVIN CRASTO Ph.D

amcrasto@gmail.com

MOBILE-+91 9323115463
GLENMARK SCIENTIST ,  INDIA
web link

View original post 149 more words

Italy’s Newron files Parkinson’s drug with FDA

New Drug Approvals

SAFINAMIDE

cas  202825-46-5 (mesylate)

N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide

Newron Pharmaceuticals and fellow Italy-headquartered partner Zambon have filed their investigational Parkinson’s disease treatment safinamide with regulators in the USA.

The submission to the US Food and Drug Administration is for safinamide as add-on therapy in early and mid-to late stage PD patients. Newron said the filing was based on “completion of activities agreed upon during meetings” with the FDA, noting that a marketing authorisation application was submitted to the European Medicines Agency in December.

Read more at: http://www.pharmatimes.com/Article/14-05-30/Italy_s_Newron_files_Parkinson_s_drug_with_FDA.aspx#ixzz33LlGLEt7

133865-89-1, Fce 26743, AC1L2ZLK, CHEMBL396778, MolPort-005-942-375,
Fce-26743, (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide
Molecular Formula: C17H19FN2O2   Molecular Weight: 302.343363

Safinamide (EMD 1195686) is a candidate drug against Parkinson’s disease with multiple methods of action.[1] In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011.[2] The compound was originally discovered at Farmitalia-Carlo…

View original post 494 more words

AMUVATINIB

New Drug Approvals

AMUVATINIB

Name N-(3,4-Methylenedioxiphenylmethyl) -4 – (benzofuro [3,2-d] pyrimidin-4-yl) piperazine-1-carbothioamide.
CAS 850879-09-3
Formula 23 H 21 N 5 O 3 S
MW 447.51
Synonim MN-470, SGI-0470-03

Amuvatinib (MP-470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.

http://www.google.co.in/patents/EP1678166A2?cl=en

Scheme 1

Figure imgf000034_0001

EXAMPLE 34 Synthesis and Analysis of Further Illustrative Compounds Compound (111-1-3), also referred to…

View original post 850 more words

AMUVATINIB

New Drug Approvals

AMUVATINIB

Name N-(3,4-Methylenedioxiphenylmethyl) -4 – (benzofuro [3,2-d] pyrimidin-4-yl) piperazine-1-carbothioamide.
CAS 850879-09-3
Formula 23 H 21 N 5 O 3 S
MW 447.51
Synonim MN-470, SGI-0470-03

Amuvatinib (MP-470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.

http://www.google.co.in/patents/EP1678166A2?cl=en

Scheme 1

Figure imgf000034_0001

EXAMPLE 34 Synthesis and Analysis of Further Illustrative Compounds Compound (111-1-3), also referred to…

View original post 850 more words